PYXS Pyxis Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782223 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin97.1%
Operating margin-554.1%
Net margin-478.9%
FCF margin-358.7%
EBITDA margin-535.6%
Returns
ROE-62.8%
ROA-46.7%
ROIC (approx.)-65.0%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio7.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $11.04M | $0 | $2.82M | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | $0 |
| Gross profit | — | — | — | — | — | — | — | $0 |
| R&D expense | $16.56M | $16.06M | $19.98M | $21.71M | $17.81M | $17.13M | $17.04M | $14.02M |
| SG&A expense | $3.97M | $9.93M | $4.38M | $5.23M | $5.65M | $5.44M | $5.87M | $5.08M |
| Operating income | -$20.52M | -$25.99M | -$24.36M | -$18.30M | -$23.46M | -$19.75M | -$22.91M | -$40.07M |
| Pretax income | -$19.98M | -$25.35M | — | -$17.00M | -$22.00M | -$18.07M | — | -$37.73M |
| Income tax | $0 | $0 | — | $1.10M | $0 | $283,000 | — | — |
| Net income | -$19.98M | -$25.35M | -$23.27M | -$18.11M | -$22.00M | -$18.35M | -$21.16M | -$35.57M |
| EBITDA | -$20.22M | -$25.69M | -$23.90M | -$15.40M | -$22.93M | -$19.21M | -$22.36M | -$39.52M |
| EPS (basic) | -0.24 | -0.40 | -0.37 | — | -0.35 | -0.30 | -0.35 | — |
| EPS (diluted) | -0.24 | -0.40 | -0.37 | — | -0.35 | -0.30 | -0.35 | — |
| Weighted avg. shares (diluted) | 83.51M | 63.99M | 63.47M | — | 62.56M | 61.92M | 61.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.86M | $18.86M | $5.77M | $15.42M | $8.92M | $10.73M | $12.76M | $19.47M |
| Short-term investments | $51.72M | $14.14M | $35.25M | $51.44M | $67.34M | $78.21M | $92.67M | $107.46M |
| Receivables | — | — | — | — | — | $3.00M | — | — |
| Current assets | $59.13M | $36.73M | $45.57M | $72.11M | $83.07M | $99.96M | $111.87M | $132.44M |
| PP&E, net | $6.94M | $7.24M | $7.54M | $8.00M | $8.46M | $8.92M | $9.40M | $9.90M |
| Intangibles | — | — | — | $0 | $2.43M | $2.49M | $2.54M | $2.60M |
| Total assets | $76.77M | $54.92M | $64.30M | $91.52M | $105.60M | $123.22M | $135.87M | $157.18M |
| Current liabilities | $19.94M | $27.47M | $16.53M | $21.13M | $19.38M | $17.68M | $14.43M | $17.68M |
| Total liabilities | $35.45M | $43.48M | $33.03M | $38.11M | $36.83M | $35.57M | $32.76M | $36.43M |
| Shareholders' equity | $41.32M | $11.44M | $31.27M | $53.41M | $68.78M | $87.64M | $103.10M | $120.75M |
| Shares outstanding | 83.51M | 63.43M | 62.83M | 62.69M | 62.15M | 62.02M | 61.63M | 59.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.29M | -$18.21M | -$26.00M | -$10.43M | -$13.28M | -$17.26M | -$22.54M | -$19.29M |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$10.43M | — | — | — | -$19.29M |
| Investing cash flow | -$37.29M | $21.30M | $16.37M | $16.26M | $11.47M | $15.30M | $15.82M | $26.66M |
| Financing cash flow | $38.59M | $9.99M | -$25,000 | $669,000 | -$8,000 | -$67,000 | $0 | $50,000 |
| Depreciation & amortization | $299,000 | $301,000 | $459,000 | $2.90M | $527,000 | $535,000 | $552,000 | $550,000 |
| Stock-based compensation | $1.33M | $5.53M | $1.21M | $2.08M | $3.07M | $3.02M | $3.63M | $2.77M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.